Copyright insider
Chemify has raised more than $50m in Series B funding. The oversubscribed round was co-led by Wing Venture Capital and Insight Partners, with participation from a syndicate including 8VC and existing backers Triatomic Capital, Blueyard, Rockspring and Eos. “Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery,” said founder and chief executive Lee Cronin. “Our vision is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry from drug discovery to new catalysts and electronic materials. “The next step in our evolution is nothing short of a revolution in the digitisation and automation of chemical discovery and manufacturing.” Earlier this year, Chemify launched its first Chemifarm, an automated chemistry facility built to be the most advanced laboratory for molecular design and synthesis. Chemifarm integrates the Chemputation platform, a programming language, advanced robotics and the world’s largest curated library of validated reactions. The new financing allows Chemify to expand this blueprint globally, building a network of digital chemistry hubs and delivering on-demand molecule design and manufacturing to pharmaceutical, biotech and materials-science partners everywhere. The Glasgow-headquartered company plans to open a Silicon Valley facility led by chief technical officer Mike Bell, to enhance its ability to deliver on-demand molecular design, optimisation and synthesis - compressing the timeline from concept to compound. Ansuman Satpathy, a partner at Wing Venture Capital, commented: “Chemify's technology uses automation and physical AI to enable the digitisation of chemistry, transforming chemical synthesis from an art to a programmable science. “We are excited to support the team’s progress as they empower scientists to create novel molecules with unmatched efficiency and precision.” Aiden Aceves, vice president at Insight Partners, remarked: “Lee is an iconoclast with the wind at his back. “Chemify's use of AI to ensure the make-ability of complex molecules is a paradigm shift for how medicinal chemistry is done today, and the company’s vision is matched by the strong results seen across their early pharma collaborations.” In conjunction with the financing, both Satpathy and Aceves have joined Chemify’s board of directors. Founded in 2022 as a spin-out from the University of Glasgow, Chemify is aiming to reinvent chemistry on a digital foundation, uniting automation, AI and data to accelerate the discovery of new medicines and advanced materials. Don't miss the latest headlines with our twice-daily newsletter - sign up here for free.
